Prakt. lékáren. 2021; 17(4): e29-e35 [Psychiatr. praxi. 2021;22(2):94-98]

Cariprazine in the treatment of schizophrenia

Eva Češková

Psychiatrická klinika LF MU a FN Brno

KPN LF Univerzity Ostrava

Oddělení psychiatrie, FN Ostrava

Cariprazine is besides aripiprazole the second partial dopamine agonist antipsychotic registered in Czech Republic for the treatment of schizophrenia. Partial dopamine receptor agonists represent the third-generation antipsychotic prototype. Cariprazine peculiar pharmacological profile may explain its efficacy on positive and negative symptoms of schizophrenia. According to the recently published algorithm cariprazine should be used as first-line treatment for patients with predominant negative symptoms. Cariprazine displays a low metabolic risk and weight gain. Among the most reported adverse events are included extrapyramidal symptoms and akathisia; however, they are usually mild, not leading in most cases to treatment interruption.

Keywords: third-generation antipsychotic, cariprazine, schizophrenia, efficacy, tolerability.

Published: December 14, 2021  Show citation